HC Wainwright Forecasts Lifeward’s Q2 Earnings (NASDAQ:LFWD)

Lifeward Ltd. (NASDAQ:LFWD) – Analysts at HC Wainwright dropped their Q2 2026 earnings estimates for Lifeward in a report issued on Tuesday, May 26th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.49) per share for the quarter, down from their previous forecast of ($0.33). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Lifeward’s current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Lifeward’s Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($4.27) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($0.83) EPS and FY2029 earnings at ($0.64) EPS.

Lifeward (NASDAQ:LFWD) last released its earnings results on Friday, May 15th. The company reported ($6.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.18) by ($5.52). The firm had revenue of $3.92 million during the quarter, compared to analyst estimates of $5.78 million. Lifeward had a negative net margin of 123.66% and a negative return on equity of 243.14%.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Lifeward in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Lifeward currently has a consensus rating of “Hold” and an average price target of $10.00.

Lifeward Price Performance

LFWD stock opened at $7.28 on Thursday. The firm has a market cap of $20.46 million, a price-to-earnings ratio of -0.37 and a beta of 0.36. The company has a quick ratio of 1.82, a current ratio of 2.40 and a debt-to-equity ratio of 1.16. Lifeward has a 12-month low of $4.14 and a 12-month high of $15.12. The company’s fifty day simple moving average is $6.90 and its 200 day simple moving average is $7.08.

Institutional Investors Weigh In On Lifeward

Several hedge funds and other institutional investors have recently bought and sold shares of LFWD. Citadel Advisors LLC increased its stake in Lifeward by 1,271.8% in the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after purchasing an additional 198,406 shares in the last quarter. Virtu Financial LLC increased its stake in Lifeward by 158.0% in the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock valued at $35,000 after purchasing an additional 37,037 shares in the last quarter. Jane Street Group LLC increased its stake in Lifeward by 77.3% in the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock valued at $40,000 after purchasing an additional 29,927 shares in the last quarter. Finally, HRT Financial LP increased its stake in Lifeward by 149.7% in the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock valued at $28,000 after purchasing an additional 29,423 shares in the last quarter. 26.76% of the stock is owned by institutional investors.

Trending Headlines about Lifeward

Here are the key news stories impacting Lifeward this week:

• Neutral Sentiment: HC Wainwright maintained a Buy rating and $10 target price on Lifeward, indicating the firm still sees upside potential despite the lower earnings outlook.
• Neutral Sentiment: The analyst also raised its FY2030 EPS estimate to $3.20 from $2.90, suggesting longer-term earnings potential may be improving. Lifeward analyst update
• Negative Sentiment: HC Wainwright lowered near-term EPS estimates for Lifeward, including Q2 2026 to a loss of $1.49 per share, Q3 2026 to a loss of $0.42, and Q4 2026 to a loss of $0.40, signaling weaker expected performance in the coming quarters. Lifeward analyst update
• Negative Sentiment: The firm also slashed FY2026 EPS expectations to a loss of $4.27 per share, which could reinforce investor concern about continued losses and cash burn. Lifeward analyst update
• Negative Sentiment: FY2027 and FY2028 EPS estimates were also reduced, extending the weaker earnings trend into future periods and potentially limiting sentiment toward the stock. Lifeward analyst update

About Lifeward

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.